---
title: "CNS Pharmaceuticals (CNSP) news: delisting and offering"
url: "https://aibio.space/companies/cns-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "CNSP delisting and offering news: CNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor. CNS Pharmaceuticals, Inc."
---

CNSP CNS Pharmaceuticals, Inc. NASDAQ · United States

# CNS Pharmaceuticals (CNSP) news CNSP delisting and offering news

Company Updates · 2026-07-02

## [CNS Pharmaceuticals lays out oncology and neurology asset search](https://aibio.space/news/cns-pharmaceuticals-lays-out-oncology-neurology-asset-search/)

The July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild.

## Latest CNS Pharmaceuticals news

1. 2026-05-04 Financings [CNS Pharmaceuticals agrees to about $22.5 million private placement with pre-funded warrants](https://aibio.space/news/cns-pharmaceuticals-agrees-about-22-5-million-private-placement-pre/) CNS Pharmaceuticals priced a private placement of common stock at $2.30 per share and pre-funded warrants at $2.299, for approximately $22.5 million gross. Most of the shares are pre-funded warrants for 9,143,479 shares. Closing is expected May 5, 2026. A director resigned and a new one was named.
2. 2025-03-31 Listings [CNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor](https://aibio.space/news/cns-pharmaceuticals-regains-nasdaq-bid-price-compliance-faces-one-year/) Nasdaq told CNS Pharmaceuticals on March 31, 2025 that it meets the $1.00 bid price rule. For one year, a new lapse leads to a delisting determination, with no compliance plan or extra time.
3. 2025-03-20 Financings [CNS Pharmaceuticals increases its at-the-market stock program to $43.5 million](https://aibio.space/news/cns-pharmaceuticals-increases-market-stock-program-43-5-million/) The company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.

## CNS Pharmaceuticals at a glance

- **Ticker**: CNSP

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $20.0 million

### Related companies

- [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) NASDAQ: TTRX
- [Coherus Oncology](https://aibio.space/companies/coherus-oncology/) NASDAQ: CHRS
- [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON
- [Viskase Holdings](https://aibio.space/companies/viskase/) OTC: VISK
- [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) NASDAQ: MGX
- [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) NASDAQ: ABUS
- [Merck & Company](https://aibio.space/companies/merck-mrk-nyse/) NYSE: MRK
- [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) NASDAQ: INDP

### Also on NASDAQ

- [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) AMLX
- [ADMA Biologics](https://aibio.space/companies/adma-biologics/) ADMA
- [Lifecore Biomedical](https://aibio.space/companies/lifecore-biomedical/) LFCR
- [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) RNTX
- [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) IPSC
- [AC Immune SA](https://aibio.space/companies/ac-immune/) ACIU

## CNS Pharmaceuticals annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) | [$9.3 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) |
| Net income (loss) | [-$15.9 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) | [-$14.9 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) |
| Cash from operations | [-$13.8 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) | [-$17.1 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) |
| Cash and equivalents | [$7.2 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826006224/) | [$6.5 million](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $20.0 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about CNS Pharmaceuticals

Was CNS Pharmaceuticals delisted?

Our latest story on this, dated Mar 31, 2025: "CNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cns-pharmaceuticals-regains-nasdaq-bid-price-compliance-faces-one-year/).

Has CNS Pharmaceuticals raised money recently?

Our latest story on this, dated May 4, 2026: "CNS Pharmaceuticals agrees to about $22.5 million private placement with pre-funded warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cns-pharmaceuticals-agrees-about-22-5-million-private-placement-pre/).

What is the ticker symbol of CNS Pharmaceuticals?

CNS Pharmaceuticals, Inc. trades under the ticker CNSP on NASDAQ.

Where is CNS Pharmaceuticals listed?

CNS Pharmaceuticals, Inc. is listed on NASDAQ.

What is the SEC CIK of CNS Pharmaceuticals?

The SEC Central Index Key (CIK) for CNS Pharmaceuticals, Inc. is 1729427. Its filings are on SEC EDGAR.

How many shares does CNS Pharmaceuticals have outstanding?

1,461,449 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is CNS Pharmaceuticals listed under?

Our directory records CNS Pharmaceuticals, Inc. under United States.

What does CNS Pharmaceuticals do?

Our directory classifies CNS Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of CNS Pharmaceuticals?

The ISIN recorded for CNS Pharmaceuticals, Inc. is US18978H5081.

Does aibio.space cover CNS Pharmaceuticals?

aibio.space lists CNS Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is CNS Pharmaceuticals incorporated?

SEC records list its state or country of incorporation as NV.

Is CNS Pharmaceuticals profitable?

CNS Pharmaceuticals, Inc. reported a net loss of $15.9 million for the fiscal year ended Dec 31, 2025, and used $13.8 million of cash in operations, per its annual report to the SEC.

How much does CNS Pharmaceuticals spend on research and development?

$9.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does CNS Pharmaceuticals have?

$20.0 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest CNS Pharmaceuticals (CNSP) stock news?

Our latest story on CNS Pharmaceuticals, dated Jul 2, 2026: "CNS Pharmaceuticals lays out oncology and neurology asset search". The July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild. [Source](https://aibio.space/news/cns-pharmaceuticals-lays-out-oncology-neurology-asset-search/).

## Investor discussion: CNS Pharmaceuticals

Members talk about CNS Pharmaceuticals (CNSP). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CNS Pharmaceuticals, newest first. Each line links the filing it comes from.

1. 2026-05-19 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316826004123/cns_s3.htm)
2. 2026-05-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316826003432/cns_8k.htm)
3. 2026-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm)
4. 2025-10-24 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825007760/cns_def14a.htm)
5. 2025-10-10 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825007498/cns_pre14a.htm)
6. 2025-09-19 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825007157/cns_424b5.htm)
7. 2025-07-22 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/cns_ex9901.htm)
8. 2025-04-14 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_s1.htm)
9. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm)
10. 2025-03-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/cns_8k.htm)
11. 2025-03-20 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm)
12. 2025-02-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825001174/cns_ex9901.htm)
13. 2025-01-03 Financings Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316825000077/cns_ex9901.htm)
14. 2024-12-03 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316824008464/cns_8k.htm)
15. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1729427/000168316824007533/cns_8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CNSP on TradingView](https://www.tradingview.com/symbols/NASDAQ-CNSP/).

## SEC filings and registration

- **SEC name**: CNS Pharmaceuticals, Inc.

- **CIK**: 1729427

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: CNSP (Nasdaq)

- **State or country of incorporation**: NV

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 2100 WEST LOOP SOUTH, HOUSTON, TX, 77027

- **Phone**: 1-800-946-9185

- **Shares outstanding**: 1,461,449 as of 2026-08-11 (10-Q filed 2026-08-12)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1729427/000168316826007552/cns_8k.htm) filed 2026-10-02
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1729427/000168316826006660/cns_idef14a.htm) filed 2026-08-21
- [10-Q](https://www.sec.gov/Archives/edgar/data/1729427/000168316826006224/cns_i10q-063026.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1729427/000168316826005233/cns_8k.htm) filed 2026-07-02
- [S-3](https://www.sec.gov/Archives/edgar/data/1729427/000168316826004123/cns_s3.htm) filed 2026-05-19
- [10-Q](https://www.sec.gov/Archives/edgar/data/1729427/000168316826003847/cns_i10q-033126.htm) filed 2026-05-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1729427/000168316826003432/cns_8k.htm) filed 2026-05-04
- [10-K](https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm) filed 2026-03-31

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001729427), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

CNS Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CNSP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: CNS Pharmaceuticals, Inc.

- **Ticker**: CNSP

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US18978H5081

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CNSP/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/cns-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CNS Pharmaceuticals (CNSP) news: delisting and offering", 2026-10-31, https://aibio.space/companies/cns-pharmaceuticals/